Article

Molecules and Cells

, Volume 29, Issue 1, pp 9-19

First online:

Mesenchymal stem cells modified with stromal cell-derived factor 1α improve cardiac remodeling via paracrine activation of hepatocyte growth factor in a rat model of myocardial infarction

  • Junming TangAffiliated withInstitute of Clinical Medicine, Renmin Hospital, Yunyang Medical CollegeDepartment of Physiology, Yunyang Medical CollegeHubei Key Laboratory of Embryonic Stem Cell Research Email author 
  • , Jianing WangAffiliated withInstitute of Clinical Medicine, Renmin Hospital, Yunyang Medical CollegeHubei Key Laboratory of Embryonic Stem Cell Research Email author 
  • , Linyun GuoAffiliated withInstitute of Clinical Medicine, Renmin Hospital, Yunyang Medical CollegeHubei Key Laboratory of Embryonic Stem Cell Research
  • , Xia KongAffiliated withInstitute of Clinical Medicine, Renmin Hospital, Yunyang Medical CollegeHubei Key Laboratory of Embryonic Stem Cell Research
  • , Jianye YangAffiliated withInstitute of Clinical Medicine, Renmin Hospital, Yunyang Medical CollegeHubei Key Laboratory of Embryonic Stem Cell Research
  • , Fei ZhengAffiliated withInstitute of Clinical Medicine, Renmin Hospital, Yunyang Medical CollegeHubei Key Laboratory of Embryonic Stem Cell Research
  • , Lei ZhangAffiliated withInstitute of Clinical Medicine, Renmin Hospital, Yunyang Medical CollegeHubei Key Laboratory of Embryonic Stem Cell Research
  • , Yongzhang HuangAffiliated withInstitute of Clinical Medicine, Renmin Hospital, Yunyang Medical CollegeHubei Key Laboratory of Embryonic Stem Cell Research

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Mesenchymal stem cells (MSCs) are a promising source for cell-based treatment of myocardial infarction (MI), but existing strategies are restricted by low cell survival and engraftment. We examined whether SDF-1 transfection improve MSC viability and paracrine action in infarcted hearts. We found SDF-1-modified MSCs effectively expressed SDF-1 for at least 21days after exposure to hypoxia. The apoptosis of Ad-SDF-1-MSCs was 42% of that seen in Ad-EGFP-MSCs and 53% of untreated MSCs. In the infarcted hearts, the number of DAPI-labeling cells in the Ad-SDF-1-MSC group was 5-fold that in the Ad-EGFP-MSC group. Importantly, expression of antifibrotic factor, HGF, was detected in cultured MSCs, and HGF expression levels were higher in Ad-SDF-MSC-treated hearts, compared with Ad-EGFP-MSC or control hearts. Compared with the control group, Ad-SDF-MSC transplantation significantly decreased the expression of collagens I and III and matrix metalloproteinase 2 and 9, but heart function was improved in d-SDF-MSC-treated animals. In conclusion, SDF-1-modified MSCs enhanced the tolerance of engrafted MSCs to hypoxic injury in vitro and improved their viability in infarcted hearts, thus helping preserve the contractile function and attenuate left ventricle (LV) remodeling, and this may be at least partly mediated by enhanced paracrine signaling from MSCs via antifibrotic factors such as HGF.

Keywords

angiogenesis HGF myocardial infarction remodeling SDF-1α stem cell